Clincosm LogoSign in Get a demo

Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01034059
Collaborator
(none)
75
Enrollment
8
Duration (Months)

Study Details

Study Description

Brief Summary

The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Patients with hematological malignancies developed neutropenia after chemotherapy. We checked the serum level of sTREM-1 in patients with neutropenic fever. Those patients were classified to 2 groups: documented infection or low likelihood of infection. Their sTREM-1 level was measured and was compared with other biomarker such as CRP and procalcitonin. The value of sTREM-1 for diagnosis of infection in patients with neutropenic fever was thus evaluated.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    75 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever
    Study Start Date :
    Oct 1, 2008
    Actual Primary Completion Date :
    Jun 1, 2009
    Actual Study Completion Date :
    Jun 1, 2009

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 84 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • chemotherapy-related neutropenia (granulocytes < 0.5 × 109/l or leukocytes < 1 × 109/l) and fever (body temperature > 38.0°C over a 6 hour observation period or body temperature ≥ 38.5°C once.
      Exclusion Criteria:

      • prolonged fever before presenting for admission,

      • antibiotics therapy in the past 72 hours,

      • more than two sites of infectious focus,

      • concomitant solid organ malignancy and blast in hemogram.

      Contacts and Locations

      Locations

      No locations specified.

      Sponsors and Collaborators

      • National Taiwan University Hospital

      Investigators

      • Principal Investigator: Szu-Chun Hsu, MD, Department of Laboratory Medicine, National Taiwan University Hospital and College of Medicine, Taipei

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT01034059
      Other Study ID Numbers:
      • 200806051R
      First Posted:
      Dec 17, 2009
      Last Update Posted:
      Dec 17, 2009
      Last Verified:
      Dec 1, 2009
      Additional relevant MeSH terms:
      Febrile Neutropenia
      Fever

      Study Results

      No Results Posted as of Dec 17, 2009